Llinks Advised Zhejiang Shapuaisi Pharmaceutical Co., Ltd. on Its Initial Public Offering and Listing

On 9 June 2014, China Securities Regulatory Commission approved Zhejiang Shapuaisi Pharmaceutical Co., Ltd., as one of the leading cataract drug manufacturers in the Chinese market for its initial public offering of 16,350,000 common shares. Zhejiang Shapuaisi Pharmaceutical Co., Ltd. was further listed on the Shanghai Stock Exchange on 2 July 2014.

As the PRC legal counsel of Zhejiang Shapuaisi Pharmaceutical Co., Ltd., Llinks advised on all aspects of its initial public offering and listing.